Trial reportBreast (Edinburgh, Scotland)2026
Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancer.
Trial report in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04148911 (An Open-Label, Phase IIIb, Single Arm, Multicenter Safety Study of Atezolizumab), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-Label, Phase IIIb, Single Arm, Multicenter Safety Study of Atezolizumab (Tecentriq) Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIMpassion130 trial results led to approval of first-line atezolizumab plus nab-paclitaxel for PD-L1-positive advanced triple-negative breast cancer (aTNBC). The global single-arm EL1SSAR study (NCT04148911) enrolled a broader patient population to elucidate outcomes in routine practice.
methodsPatients with measurable PD-L1-positive aTNBC and no prior systemic therapy for advanced disease received atezolizumab (840 mg, days 1&15) plus nab-paclitaxel (100 mg/m
resultsAmong 182 treated patients, five had CNS metastases and three had ECOG PS ≥ 2. Patients received a median of six treatment cycles (range 1-63); 7% were treated for >3 years. Grade ≥2 immune-mediated AEs occurred in 12% of patients (95% CI 8%-18%) and grade ≥3 AEs in 47% (95% CI 39%-54%). There were no treatment-related deaths. Median PFS was 7.4 (95% CI 5.6-10.6) months (>2 years in 27 patients [15%]) and median overall survival was 27.0 (95% CI 22.0-33.8) months. Concordance between local and central PD-L1 testing was 67% (65/97). Median PFS was >11 months in patients with centrally confirmed PD-L1-positive status.
conclusionsSafety and efficacy were consistent with results from IMpassion130, which enrolled a more selected population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.